资讯

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial
By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...
Clinical Trials Arena4 天
ASCO25: Trodelvy and Keytruda to become new standard of care for frontline TNBC
Annual Meeting, held 30 May-3 June 2025, primary results were presented from the ASCENT-04/KEYNOTE-D19 study investigating ...
Fierce Pharma6 天
ASCO: Gilead bolsters Trodelvy in triple-negative breast cancer with practice-changing ...
In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...
STAT6 天
Combination treatment reduces risk of tumor progression in aggressive form of breast cancer ...
The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
The ASCENT-04/KEYNOTE-D19 study is a global, open-label, randomized phase III study evaluating the efficacy and safety of ...
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer ...
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...
pharmaphorum5 天
ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC
Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...
Nasdaq4 天
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study
Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study. Data from the phase III ASCENT-04 ...